<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559676</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574159</org_study_id>
    <secondary_id>CHUL-BIO-COLON</secondary_id>
    <secondary_id>INCA-RECF0356</secondary_id>
    <nct_id>NCT00559676</nct_id>
  </id_info>
  <brief_title>Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospital Regional Universitaire de Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with&#xD;
      cancer receiving chemotherapy may help doctors understand the effect of chemotherapy on&#xD;
      biomarkers. It may also help doctors predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This phase IV trial is studying biomarkers in patients undergoing chemotherapy for&#xD;
      metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Research the oncogenetic parameters and pharmacogenetic and pharmacokinetic predictors&#xD;
           of therapeutic response and toxic effects.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Study the correlations between the pharmacogenetic and pharmacokinetic parameters.&#xD;
&#xD;
        -  Study the predictive value of these parameters on disease-free and overall survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 1 of 4 chemotherapy regimens:&#xD;
&#xD;
        -  Regimen 1: Fluorouracil and leucovorin calcium&#xD;
&#xD;
        -  Regimen 2: Capecitabine and leucovorin calcium&#xD;
&#xD;
        -  Regimen 3: Irinotecan hydrochloride&#xD;
&#xD;
        -  Regimen 4: Oxaliplatin Tumor and blood samples are collected before the start of&#xD;
           chemotherapy and are examined by pharmacogenetic analysis. Clinical and biological&#xD;
           parameters are also studied. Blood samples are also collected during the first course of&#xD;
           chemotherapy for pharmacokinetic studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Oncogenetic parameters</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacogenetic and pharmacokinetic predictors of therapeutic response and toxic effects</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations between the pharmacogenetic and pharmacokinetic parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of pharmacogenetic and pharmacokinetic parameters on disease-free and overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal cancer&#xD;
&#xD;
               -  Unresectable metastatic disease must be confirmed histologically if &gt; 2 years&#xD;
                  since primary diagnosis&#xD;
&#xD;
          -  Measurable metastatic disease &gt; 1 cm by spiral CT scan or &gt; 2 cm by other methods&#xD;
&#xD;
          -  Scheduled to receive first-line chemotherapy for metastatic disease&#xD;
&#xD;
               -  Chemotherapy must include fluorouracil, capecitabine, irinotecan hydrochloride,&#xD;
                  or oxaliplatin&#xD;
&#xD;
          -  No inadequate or unusable tissue as the only tissue available&#xD;
&#xD;
          -  No known brain metastases or meningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  No contraindication to chemotherapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other severe pathology that is likely to worsen during therapy&#xD;
&#xD;
          -  No dementia or severely impaired mental condition&#xD;
&#xD;
          -  No geographical or psychological reasons that would preclude treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior therapy for metastatic cancer&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  Concurrent bevacizumab or other monoclonal antibody therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Tubiana-Mathieu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospital Regional Universitaire de Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

